TRexBio prices IPO at $14 per share on Nasdaq

TRex Bio, Inc. (Nasdaq: TRXB), a clinical-stage biotechnology company, priced its initial public offering of 8,333,334 shares of common stock at $14.00 per share, according to a press release statement.

The gross proceeds from the offering are expected to be approximately $116.7 million before deducting underwriting discounts, commissions, and other expenses. All shares are being offered by TRexBio.

The company's common stock was expected to begin trading on the Nasdaq Global Select Market on Oct. 9, 2026, under the ticker symbol "TRXB," with the offering expected to close on Oct. 13, 2026, subject to customary closing conditions.

TRexBio has also granted underwriters a 30-day option to purchase up to an additional 1,250,000 shares at the initial public offering price, less underwriting discounts and commissions.

J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager.

The company is focused on tissue regulatory T-cell biology for the development of treatments targeting autoimmune and inflammatory diseases. TRexBio is headquartered in South San Francisco, California.

You May Also Be Interested In

• Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq
• bioAffinity Technologies raises ~$4M in stock offering via WallachBeth
• Fossil Group adds two directors, names new board chair